Leqvio (inclisiran) is not a traditional biologic like the monoclonal antibody cholesterol drugs you may be comparing it to. It is a chemically synthesized small interfering RNA, which places it in a newer, distinct drug category. While it targets a biological process inside your cells, its manufacturing and molecular structure differ fundamentally from classic biologics like Repatha or Praluent.
What Leqvio Actually Is
Leqvio is a short-chain, synthetic small interfering RNA (siRNA). Traditional biologics are large, complex proteins grown in living cell cultures, typically engineered immune cells. Leqvio, by contrast, is built through chemical synthesis of nucleic acid sequences. It’s a much smaller molecule than a monoclonal antibody, and it works through an entirely different mechanism.
The FDA has approved Leqvio as an add-on to diet, exercise, and maximally tolerated statin therapy to reduce LDL cholesterol in adults with high cholesterol, including those with an inherited form called heterozygous familial hypercholesterolemia (HeFH).
How Leqvio Works Inside Your Body
Leqvio hijacks a natural process called RNA interference to stop your liver from making a protein called PCSK9. That protein normally breaks down the receptors on liver cells that pull LDL (“bad”) cholesterol out of your bloodstream. By silencing the gene that produces PCSK9, Leqvio lets more of those receptors survive and do their job, clearing more cholesterol from your blood.
A sugar molecule attached to Leqvio (called GalNAc) acts as a homing signal that directs the drug specifically to liver cells. This limits exposure throughout the rest of your body. Once inside a liver cell, the siRNA pairs with the messenger RNA that carries instructions for building PCSK9 and triggers its destruction. The effect is durable: in clinical trials, Leqvio delivered an average LDL cholesterol reduction of about 50 to 60% over a year.
How It Differs From PCSK9 Monoclonal Antibodies
Repatha (evolocumab) and Praluent (alirocumab) are monoclonal antibodies, which are true biologics. They are large protein molecules produced in living cell lines. These drugs work by floating through your bloodstream and physically binding to PCSK9 protein after it has already been made, blocking it from attaching to LDL receptors on liver cells.
Leqvio works one step earlier. Instead of blocking PCSK9 after it’s produced, it prevents the protein from being made in the first place by destroying the genetic instructions inside the cell. This upstream approach is why a single Leqvio injection lasts much longer. Monoclonal antibodies need to be injected every two to four weeks. Leqvio requires just two injections per year after the initial loading period.
The Dosing Schedule
Leqvio is given as a subcutaneous injection (under the skin) by a healthcare provider. You receive your first dose, a second dose at 3 months, and then one injection every 6 months after that. This twice-yearly maintenance schedule is one of the drug’s main practical advantages, since you don’t need to self-inject at home or remember frequent doses.
Common Side Effects
The most frequently reported side effects are injection site reactions: pain, redness, swelling, itching, or rash where the shot was given. Some people also experience joint pain, muscle stiffness, or headache. Because the drug is targeted specifically to liver cells, it has limited systemic exposure, which helps keep the side effect profile relatively narrow compared to drugs that circulate broadly throughout the body.
Why the Classification Matters
Whether Leqvio counts as a “biologic” matters for practical reasons, including insurance coverage, pharmacy benefit classification, and how the drug is regulated. Regulatory agencies generally classify siRNA therapies separately from traditional biologics. Leqvio was approved through the FDA’s standard new drug application pathway, not the biologics license application pathway used for monoclonal antibodies. In a strict regulatory sense, it is not classified as a biologic.
That said, you’ll sometimes see Leqvio grouped loosely with biologics in casual medical discussions because it targets a biological pathway at the genetic level and is injected rather than taken as a pill. The distinction is real but can be blurry depending on context. If your insurance or pharmacy is asking whether it’s a biologic for coverage purposes, the accurate answer is that it is a synthetic nucleic acid therapy, not a biologic in the traditional regulatory definition.